Cerus Corporation Makes Significant Strides in Red Blood Cell Programs
Cerus Corporation (Nasdaq:CERS) has recently heralded vital advancements in their INTERCEPT red blood cell (RBC) programs across the U.S. and Europe. With pivotal support from the Biomedical Advanced Research and Development Authority (BARDA), Cerus is poised for continued progress in enhancing the safety and effectiveness of blood transfusions performed globally.
BARDA Contract to Enhance U.S. RBC Program
The commitment from BARDA encapsulates a new six-year agreement valued at up to $248 million. This significant funding will not only facilitate further research into the INTERCEPT RBC system but also enhance plans for U.S. Food and Drug Administration (FDA) regulatory pathways, such as a modular premarket approval (PMA) application. The initial funding phase, which amounts to $32.1 million, will kickstart various project activities, focusing on developing an advanced product candidate alongside scaling up manufacturing operations to supply potential consumer needs.
Positive Results Reinforce Confidence
Recent achievements in clinical trials signal a promising future for Cerus. In a notable March release, Cerus announced overwhelmingly positive topline results from their BARDA-funded ReCePI study, which is a significant U.S. Phase 3 clinical trial. This study concluded that INTERCEPT RBCs are non-inferior to conventional RBCs when administered to patients undergoing complex cardiac surgical procedures. Moreover, Cerus is actively recruiting participants for their ongoing RedeS trial, the second pivotal Phase 3 study aimed at patient populations that require RBC transfusions due to acute and chronic anemia.
European Regulatory Journey
While the U.S. program is gaining momentum, Cerus is navigating a complex landscape in Europe. The recent CE Mark review did not yield the expected approval. Those results stemmed from a comprehensive assessment by both TÜV-SÜD, the Notified Body, and CBG-MEB, the Competent Authority, raising essential questions about the adequacy of the submitted data regarding the impurity profile of the final product.
Strategizing for Future Filings
Cerus remains proactive and is working closely with TÜV-SÜD to brainstorm strategies for a successful resubmission. The company firmly believes in the pressing need for pathogen-inactivated RBCs and is diligently reassessing its regulatory dossier to incorporate additional supporting data collected since the original submission. Cerus seeks to leverage positive outcomes from recent clinical studies, including those from their trials in the U.S., as part of this renewed submission effort.
Webcast and Investor Engagement
In light of these developments, Cerus will be hosting a webcast to provide an in-depth update on their INTERCEPT red blood cell program. Scheduled for 5:00 P.M. EDT, this interactive session will allow stakeholders to engage with management and gain clearer insights into the company’s future trajectory. Following the live event, a replay will be available for those unable to attend.
About Cerus Corporation
Dedicated to ensuring the world’s blood supply is safe and pathogen-free, Cerus Corporation continues to innovate and apply its expertise in blood technology. The company's INTERCEPT Blood System for platelets and plasma has achieved global recognition along with CE mark and FDA approvals. With the INTERCEPT RBC system currently in late-stage clinical development, the organization is focused on delivering essential products that alleviate the risks associated with blood transfusions.
Frequently Asked Questions
What is the INTERCEPT RBC program?
The INTERCEPT RBC program is developed by Cerus Corporation with the aim of enhancing the safety of red blood cell transfusions through pathogen inactivation technology.
What support has BARDA provided?
BARD has provided a substantial funding commitment of up to $248 million to assist Cerus in the advancement of the INTERCEPT RBC system, covering FDA application expenses and further developmental activities.
Are there any upcoming clinical trials?
Yes, Cerus is currently enrolling patients in its BARDA-funded RedeS clinical trial, aimed at testing the efficacy of INTERCEPT RBC transfusions in patients with anemia.
What challenges is Cerus facing in Europe?
Cerus faced a setback with its CE Mark application after the regulatory authority requested more data on impurity profiles, which delayed approval.
How can stakeholders stay updated?
Cerus will host webcasts and provide updates on their Investor Relations page, allowing stakeholders to remain informed of recent developments.
